|
1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferenci P, Fried M, Labrecque D, Bruix J,
Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA,
et al: Hepatocellular carcinoma (HCC): A global perspective. J Clin
Gastroenterol. 44:239–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oliveri RS, Wetterslev J and Gluud C:
Transarterial (chemo)embolisation for unresectable hepatocellular
carcinoma. Cochrane Database Syst Rev. 3:CD0047872011.
|
|
4
|
Feng M and Ben-Josef E: Radiation therapy
for hepatocellular carcinoma. Semin Radiat Oncol. 21:271–277. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marrero JA, Feng Z, Wang Y, Nguyen MH,
Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D,
et al: Alpha-fetoprotein, des-gamma carboxyprothrombin, and
lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Gastroenterology. 137:110–118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baig JA, Alam JM, Mahmood SR, Baig M,
Shaheen R, Sultana I and Waheed A: Hepatocellular carcinoma (HCC)
and diagnostic significance of A-fetoprotein (AFP). J Ayub Med Coll
Abbottabad. 21:72–75. 2009.PubMed/NCBI
|
|
7
|
Collier J and Sherman M: Screening for
hepatocellular carcinoma. Hepatology. 27:273–278. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaker O, Alhelf M, Morcos G and
Elsharkawy A: miRNA-101-1 and miRNA-221 expressions and their
polymorphisms as biomarkers for early diagnosis of hepatocellular
carcinoma. Infect Genet Evol. 51:173–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye W, Li J, Fang G, Cai X, Zhang Y, Zhou
C, Chen L and Yang W: Expression of microRNA 638 and
sex-determining region Y-box 2 in hepatocellular carcinoma:
Association between clinicopathological features and prognosis.
Oncol Lett. 15:7255–7264. 2018.PubMed/NCBI
|
|
10
|
Li F, Wang F, Zhu C, Wei Q, Zhang T and
Zhou YL: miR-221 suppression through nanoparticle-based miRNA
delivery system for hepatocellular carcinoma therapy and its
diagnosis as a potential biomarker. Int J Nanomed. 13:2295–2307.
2018. View Article : Google Scholar
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hua HW, Jiang F, Huang Q, Liao Z and Ding
G: MicroRNA-153 promotes Wnt/β-catenin activation in hepatocellular
carcinoma through suppression of WWOX. Oncotarget. 6:3840–3847.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu LM, Ji JS, Yang Z, Xing CY, Pan TT, Xie
HY, Zhang F, Zhuang L, Zhou L and Zheng SS: Oncogenic role of
microRNA-423-5p in hepatocellular carcinoma. Hepatobiliary Pancreat
Dis Int. 14:613–618. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burchard J, Zhang C, Liu AM, Poon RT, Lee
NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al:
microRNA-122 as a regulator of mitochondrial metabolic gene network
in hepatocellular carcinoma. Mol Syst Biol. 6:4022010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hutter C and Zenklusen JC: The cancer
genome atlas: Creating lasting value beyond its data. Cell.
173:283–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Danford T, Rolfe A and Gifford D: GSE: A
comprehensive database system for the representation, retrieval,
and analysis of microarray data. Pac Symp Biocomput. 1–550.
2008.
|
|
19
|
Lee M and Lee H: DMirNet: Inferring direct
microRNA-mRNA association networks. BMC Syst Biol. 10:1252016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang S, Xie Y, Yang P, Chen P and Zhang
L: HCV core protein-induced down-regulation of microRNA-152
promoted aberrant proliferation by regulating Wnt1 in HepG2 cells.
PLoS One. 9:e817302014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiao X, Sherman BT, da Huang W, Stephens
R, Baseler MW, Lane HC and Lempicki RA: DAVID-WS: A stateful web
service to facilitate gene/protein list analysis. Bioinformatics.
28:1805–1806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Budhu A, Jia HL, Forgues M, Liu CG,
Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, et al:
Identification of metastasis-related microRNAs in hepatocellular
carcinoma. Hepatology. 47:897–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y
and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular
carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer
Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li W, Xie L, He X, Li J, Tu K, Wei L, Wu
J, Guo Y, Ma X, Zhang P, et al: Diagnostic and prognostic
implications of microRNAs in human hepatocellular carcinoma. Int J
Cancer. 123:1616–1622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sato F, Hatano E, Kitamura K, Myomoto A,
Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S and
Shimizu K: MicroRNA profile predicts recurrence after resection in
patients with hepatocellular carcinoma within the Milan Criteria.
PLoS One. 6:e164352011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cairo S, Wang Y, de Reyniès A, Duroure K,
Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM and
Buendia MA: Stem cell-like micro-RNA signature driven by Myc in
aggressive liver cancer. Proc Natl Acad Sci USA. 107:20471–20476.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Noh JH, Chang YG, Kim MG, Jung KH, Kim JK,
Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, et al: MiR-145 functions
as a tumor suppressor by directly targeting histone deacetylase 2
in liver cancer. Cancer Lett. 335:455–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han K, Li J, Zhao H, Liang P, Huang X,
Zheng L, Li Y, Yang T and Wang L: Identification of the typical
miRNAs and target genes in hepatocellular carcinoma. Mol Med Rep.
10:229–235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Diaz G, Melis M, Tice A, Kleiner DE,
Mishra L, Zamboni F and Farci P: Identification of microRNAs
specifically expressed in hepatitis C virus-associated
hepatocellular carcinoma. Int J Cancer. 133:816–824. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen J, Wang A, Wang Q, Gurvich I, Siegel
AB, Remotti H and Santella RM: Exploration of genome-wide
circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a
potential biomarker. Cancer Epidemiol Biomarkers Prev.
22:2364–2373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang DH, Wang GY, Zhang JW, Li Y, Zeng XC
and Jiang N: miR-501-5p regulates CYLD expression and promotes cell
proliferation in human hepatocellular carcinoma. Jpn J Clin Oncol.
45:738–744. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao L and Zhang Y: miR-342-3p affects
hepatocellular carcinoma cell proliferation via regulating NF-κB
pathway. Biochem Biophys Res Commun. 457:370–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Murakami Y, Kubo S, Tamori A, Itami S,
Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T and Taguchi YH:
Comprehensive analysis of transcriptome and metabolome analysis in
intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Sci
Rep. 5:162942015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ding W, Yang H, Gong S, Shi W, Xiao J, Gu
J, Wang Y and He B: Candidate miRNAs and pathogenesis investigation
for hepatocellular carcinoma based on bioinformatics analysis.
Oncol Lett. 13:3409–3414. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Martinez-Quetglas I, Pinyol R, Dauch D,
Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A,
Rodriguez-Carunchio L, Solé M, et al: IGF2 Is up-regulated by
epigenetic mechanisms in hepatocellular carcinomas and is an
actionable oncogene product in experimental models.
Gastroenterology. 151:1192–1205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ,
Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, et al: A serum microRNA
classifier for early detection of hepatocellular carcinoma: A
multicentre, retrospective, longitudinal biomarker identification
study with a nested case-control study. Lancet Oncol. 16:804–815.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liese J, Peveling-Oberhag J, Doering C,
Schnitzbauer AA, Herrmann E, Zangos S, Hansmann ML, Moench C,
Welker MW, Zeuzem S, et al: A possible role of microRNAs as
predictive markers for the recurrence of hepatocellular carcinoma
after liver transplantation. Transpl Int. 29:369–380. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu LN, Huang DF, Li F, et al: Diagnostic
value of serum miRNA-122 and miRNA-221 expression in patients with
primary liver cancer. Jiangsu Med J. 41:1285–1288. 2015.(In
Chinese).
|
|
42
|
Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X,
Zhou X and Gan J: A serum microRNA panel as potential biomarkers
for hepatocellular carcinoma related with hepatitis B virus. PLoS
One. 9:e1079862014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu J, Wu C, Che X, Wang L, Yu D, Zhang T,
Huang L, Li H, Tan W, Wang C and Lin D: Circulating microRNAs,
miR-21, miR-122, and miR-223, in patients with hepatocellular
carcinoma or chronic hepatitis. Mol Carcinog. 50:136–142. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Qi P, Cheng SQ, Wang H, Li N, Chen YF and
Gao CF: Serum microRNAs as biomarkers for hepatocellular carcinoma
in Chinese patients with chronic hepatitis B virus infection. PLoS
One. 6:e284862011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hsu SH, Wang B, Kota J, Yu J, Costinean S,
Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, et al: Essential
metabolic, anti-inflammatory, and anti-tumorigenic functions of
miR-122 in liver. J Clin Invest. 122:2871–2883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang
WJ, Yang L, Fu Q, Xu JJ and Gu JX: Decreased expression of
hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in
hepatitis B virus-associated hepatocellular carcinoma enhances
potential oncogenic GALNT10 protein activity. J Biol Chem.
290:1170–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li G, Shen Q, Li C, Li D, Chen J and He M:
Identification of circulating MicroRNAs as novel potential
biomarkers for hepatocellular carcinoma detection: A systematic
review and meta-analysis. Clin Transl Oncol. 17:684–693. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
He S, Hu XW, Wang D, Han LF, Zhang DC and
Wei C: Accuracy of microRNAs for the diagnosis of hepatocellular
carcinoma: A systematic review and meta-analysis. Clin Res Hepatol
Gastroenterol. 40:405–417. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang JT, Liu SM, Ma H, Yang Y, Zhang X,
Sun H, Zhang X, Xu J and Wang J: Systematic review and
meta-analysis: Circulating miRNAs for diagnosis of hepatocellular
carcinoma. J Cell Physiol. 231:328–335. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Borlado LR and Méndez J: CDC6: From DNA
replication to cell cycle checkpoints and oncogenesis.
Carcinogenesis. 29:237–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Deng Y, Jiang L, Wang Y, Xi Q, Zhong J,
Liu J, Yang S, Liu R, Wang J, Huang M, et al: High expression of
CDC6 is associated with accelerated cell proliferation and poor
prognosis of epithelial ovarian cancer. Pathol Res Pract.
212:239–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen S, Chen X, Xie G, He Y, Yan D, Zheng
D, Li S, Fu X, Li Y, Pang X, et al: Cdc6 contributes to
cisplatin-resistance by activation of ATR-Chk1 pathway in bladder
cancer cells. Oncotarget. 7:40362–40376. 2016.PubMed/NCBI
|
|
53
|
Lee CF, Ling ZQ, Zhao T, Fang SH, Chang
WC, Lee SC and Lee KR: Genomic-wide analysis of lymphatic
metastasis-associated genes in human hepatocellular carcinoma.
World J Gastroenterol. 15:356–365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Notas G, Alexaki VI, Kampa M, Pelekanou V,
Charalampopoulos I, Sabour-Alaoui S, Pediaditakis I, Dessirier V,
Gravanis A, Stathopoulos EN, et al: APRIL binding to BCMA activates
a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest
in liver cells. J Immunol. 189:4748–4758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xiong XD, Fang JH, Qiu FE, Zhao J, Cheng
J, Yuan Y, Li SP and Zhuang SM: A novel functional polymorphism in
the Cdc6 promoter is associated with the risk for hepatocellular
carcinoma. Mutat Res. 643:70–74. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kosakowska-Cholody T, Cholody WM,
Hariprakasha HK, Monks AP, Kar SP, Wang M, Michejda CJ and Carr B
1: Growth inhibition of hepatocellular carcinoma cells in vitro and
in vivo by the 8-methoxy analog of WMC79. Cancer Chemother
Pharmacol. 63:769–778. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gan N, Du Y, Zhang W and Zhou J: Increase
of Mcm3 and Mcm4 expression in cervical squamous cell carcinomas.
Eur J Gynaecol Oncol. 31:291–294. 2010.PubMed/NCBI
|
|
58
|
Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi
E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y,
et al: Minichromosome maintenance (MCM) protein 4 as a marker for
proliferation and its clinical and clinicopathological significance
in non-small cell lung cancer. Lung Cancer. 72:229–237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lian M, Fang J, Han D, Ma H, Feng L, Wang
R and Yang F: Microarray gene expression analysis of tumorigenesis
and regional lymph node metastasis in laryngeal squamous cell
carcinoma. PLoS One. 8:e848542013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Studach LL, Menne S, Cairo S, Buendia MA,
Hullinger RL, Lefrançois L, Merle P and Andrisani OM: Subset of
Suz12/PRC2 target genes is activated during hepatitis B virus
replication and liver carcinogenesis associated with HBV X protein.
Hepatology. 56:1240–1251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nan YL, Hu YL, Liu ZK, Duan FF, Xu Y, Li
S, Li T, Chen DF and Zeng XY: Relationships between cell cycle
pathway gene polymorphisms and risk of hepatocellular carcinoma.
World J Gastroenterol. 22:5558–5567. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Stolk L, Zhai G, van Meurs JB, Verbiest
MM, Visser JA, Estrada K, Rivadeneira F, Williams FM, Cherkas L,
Deloukas P, et al: Loci at chromosomes 13, 19 and 20 influence age
at natural menopause. Nat Genet. 41:645–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cai L, Zhao K and Yuan X: Expression of
minichromosome maintenance 8 in chronic myelogenous leukemia. Int J
Clin Exp Pathol. 8:14180–14188. 2015.PubMed/NCBI
|
|
64
|
Peng YP, Zhu Y, Yin LD, Zhang JJ, Guo S,
Fu Y, Miao Y and Wei JS: The expression and prognostic roles of
MCMs in pancreatic cancer. PLoS One. 11:e01641502016. View Article : Google Scholar : PubMed/NCBI
|
